YC Therapeutics startups
65 Y Combinator companies in Therapeutics, 3 of them from the last four batches. Its share of recent batches is 0.4%, down from 0.5% in the four batches before. About 23% are AI companies by YC’s tags.
- Signal
- Open
- Since 2025
- 6 vs 9 in 2023–24
- Acquired or public
- 7%
- Listed as inactive
- 17%
Share of each batch
Therapeutics companies as a share of each YC batch since 2015.
Newest entrants
Of 42 Therapeutics companies from batches up to 2021, YC lists 3 as acquired, 0 as public, 32 as active and 7 as inactive.
- Nxtcure Labs F26 · The full-stack AI CRO for drug discovery.
- WonderTx S26 · Extrapolative AI to unlock First-in-Class drugs
- FinalDose X26 · Programmable DNA drug destroying all cancers, unlocking 80% of targets
Building in Therapeutics?
Open problems and funding on Questd for longevity.
- Y Combinator · Requests for Startups
- Andreessen Horowitz · Big Ideas 2026
- New Enterprise Associates · Investment Focus 2026
- GV · Investment Focus 2026
Therapeutics companies, newest first
65 companies
- Nxtcure Labs
The full-stack AI CRO for drug discovery.
Fall 2026TherapeuticsSan Francisco, CA, USA - WonderTxAI
Extrapolative AI to unlock First-in-Class drugs
Summer 2026Therapeutics3San Francisco, CA, USA - FinalDoseAI
Programmable DNA drug destroying all cancers, unlocking 80% of targets
Spring 2026Therapeutics5Oxford, England, United Kingdom - Blank Bio
RNA intelligence for precision medicine
Summer 2025Therapeutics6San Francisco, CA, USA - Exin Therapeutics
AI drug discovery platform for neurotherapeutics
Winter 2025Therapeutics9San Francisco, CA, USA - Uncommon Therapeutics
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Winter 2025Therapeutics2San Francisco, CA, USA - Evolvere BioSciencesAI
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
Summer 2024Therapeutics3Oxford, England, United Kingdom - Kopra Bio
Genetically engineered viruses that teach your immune system to kill…
Summer 2024Therapeutics2San Francisco, CA, USA - Eris Biotech
Our drugs engage the immune system to fight tumors
Winter 2024Therapeutics2Salt Lake City, UT, USA - Granza Bio
Building programmable therapeutics for the immune system
Winter 2024Therapeutics8San Francisco, CA, USA - Junction Bioscience
AI Hypothesis Engine for Molecular Discovery
Winter 2024TherapeuticsNew York City, NY, USA - ParcelBio
Elevated mRNA for transformative medicines.
Winter 2024Therapeutics6San Francisco, CA, USA - SynsoryBio
"If-then" conditional logic for protein drugs
Winter 2024Therapeutics2Boston, MA, USA - Velorum Therapeutics
Breakthrough medicines unlocking the biology of heme
Winter 2024Therapeutics5San Francisco, CA, USA - Modulari-T
We teach your immune system to attack and cure cancer
Winter 2023Therapeutics4Montreal, QC, Canada - Eugit Therapeutics
Enabling Tissue Targeting of Therapies
Summer 2022Therapeutics2San Francisco, CA, USA - Guardian Bio
Dendritic cell-based platform for cancer therapy
Summer 2022Therapeutics2Boston, MA, USA - KeylikaAI
Redefining the Standard of Care for Iron Deficiency Anemia
Summer 2022Therapeutics1San Francisco, CA, USA - Relevium Medical
Platform injectable gel based therapeutic for osteoarthritis
Summer 2022Therapeutics5Galway, County Galway, Ireland - Serinus Biosciences
Combinations therapy by rational design
Summer 2022Therapeutics6New York City, NY, USA - Alixia
Targeting the Tumor Ecosystem to address cancer drug resistance.
Winter 2022Therapeutics2San Francisco, CA, USA - Engage Bio
Potent, durable, and redosable non-viral genetic medicines
Winter 2022Therapeutics10San Francisco, CA, USAAcquired - Origami Therapeutics, Inc.
Oral drugs to halt neurodegeneration
Winter 2022Therapeutics4San Diego, CA, USA - Catena Biosciences
Using protein coupling to build new therapies
Summer 2021Therapeutics7San Francisco, CA, USA
Sector is YC’s own label in its public company directory. See the methodology, every sector side by side, or browse open problems worth solving.